International Stem Cell net loss turns to USD 71,000 in Q2 FY26; product sales rise 9% to USD 2.68 million vs Q2 FY25

• International Stem Cell posted a net loss of $71,000 for the quarter ended June 30, 2026, versus net income of $129,000 a year earlier.
• Product sales rose 9% to $2.68 million, while cost of sales climbed 31% to $1.22 million.
• General and administrative expenses increased 17% to $1.06 million, driven by higher legal and consulting costs tied to strategic activities.
• Research and development spending edged down 4% to $155,000, while selling and marketing costs slipped 3% to $276,000.
• The company reiterated it has no revenue from therapeutic product development and cited substantial doubt about its ability to continue as a going concern.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. International Stem Cell Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-349108), on August 13, 2026, and is solely responsible for the information contained therein.